Current guidelines for the management of Lyme borreliosis in European countries
DOI:
https://doi.org/10.12775/JEHS.2025.77.57133Keywords
Lyme disease, guidelines, Borrelia burgdorferi, managementAbstract
Introduction and purpose:
Lyme borreliosis, caused by Borrelia burgdorferi sensu lato complex, is the most common vector-borne disease in Europe. Transmitted by Ixodes ticks, its prevalence is increasing due to climate change, expanded tick habitats, and improved diagnostic awareness. Consequently, unified and evidence-based management guidelines are critical to ensure consistent diagnosis and treatment across European countries. This article provides an overview of current guidelines from 2023 for the management of Lyme borreliosis in Europe.
Materials and methods:
A literature search was conducted by analysing scientific articles published in Google Scholar, PubMed, and UpToDate using keywords included: Lyme disease; guidelines; Borrelia burgdorferi; management. We also searched current guidelines of Polish Society of Epidemiology and Infectious Diseases and recommendations from other European countries.
Description of the state of knowledge:
There are 3 stages of Lyme disease: early localized, early disseminated and late. Clinical diagnosis is based on symptoms, history of tick exposure, and observation of erythema migrans. To confirm Lyme disease, laboratory tests must also be performed. Lyme borreliosis is typically treated with antibiotics depending on the character.
Conclusion:
European guidelines for Lyme borreliosis emphasize early diagnosis and appropriate antibiotic therapy based on disease stage. Preventive measures and public health initiatives are essential to reduce the disease burden. While current guidelines ensure effective management, continued harmonization and advancements in diagnostics, treatment, and vaccine development will further enhance Lyme borreliosis care across Europe.
Keywords: Lyme disease; guidelines; Borrelia burgdorferi; management.
References
1. Gomes-Solecki M, Arnaboldi PM, Backenson PB, Benach JL, Cooper CL, Dattwyler RJ, Diuk-Wasser M, Fikrig E, Hovius JW, Laegreid W, Lundberg U, Marconi RT, Marques AR, Molloy P, Narasimhan S, Pal U, Pedra JHF, Plotkin S, Rock DL, Rosa P, Telford SR, Tsao J, Yang XF, Schutzer SE. Protective Immunity and New Vaccines for Lyme Disease. Clin Infect Dis. 2020 Apr 10;70(8):1768-1773. doi: 10.1093/cid/ciz872. PMID: 31620776; PMCID: PMC7155782.
2. Bézay N, Hochreiter R, Kadlecek V, Wressnigg N, Larcher-Senn J, Klingler A, Dubischar K, Eder-Lingelbach S, Leroux-Roels I, Leroux-Roels G, Bender W. Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults. Lancet Infect Dis. 2023 Oct;23(10):1186-1196. doi: 10.1016/S1473-3099(23)00210-4. Epub 2023 Jul 4. PMID: 37419129.
3. Burn L., Tran T.M.P., Pilz A. and others.: Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005–2020). Vector Borne Zoonotic Dis., 2023; 23: 156–171.
4. Wilking H., Stark K.: Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009–2012. Ticks Tick-borne Dis., 2014; 5: 219–224.
5. Steere A.C., Strle F., Wormser G.P. and others.: Lyme borreliosis. Nat. Rev. Dis. Primers, 2016; 2: 16 090.
6. Stanek G., Fingerle V., Hunfeld K.P. and others.: Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin. Microbiol. Infect., 2011; 17: 69–79.
7. 7. Sanchez E., Vannier E., Wormser G.P., Hu L.T.: Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA 2016; 315: 1767–77.
8. Maraspin V., Ogrinc K., Ružić-Sabljić E., Lotrič-Furlan S., Strle F.: Isolation of Borrelia burgdorferi sensu lato from blood of adult patients with borrelial lymphocytoma, Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. Infection, 2011; 39: 35–40.
9. Rauer S., Kastenbauer S., Hofmann H. and others.: Guidelines for diagnosis and treatment in neurology – Lyme neuroborreliosis. Ger. Med. Sci., 2020; 18: 1–29.
10. Lantos P.M., Rumbaugh J., Bockenstedt L.K. and others.: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin. Infect. Dis., 2021; 72: 1–8.
11. Malinowski A., Czupryna P., Mrugacz M.: Eye disorders in the course of tick-borne diseases. Ophthalmologist's Magazine, 2018; 12: 145–150.
12. N’Guyen Y., Lesaffre F., Metz D., de Martino S., Jaulhac B., Andréoletti L.: No serological evidence for Borrelia burgdorferi sensu lato infection in patients with dilated cardiomyopathy in Northern France. Infect. Dis. (Lond), 2016; 48: 763–764.
13. Pancewicz S., Moniuszko-Malinowska A., Garlicki A. and others.: Diagnosis and treatment of Lyme borreliosis. Recommendations of the Polish Society of Epidemiologists and Infectious Disease Physicians – 2018. Standards and guidelines.
14. Oteo J.A., Corominas H., Escudero R.: Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Spanish Society of Neurology (SEN), Spanish Society of Immunology (SEI), Spanish Society of Pediatric Infectology (SEIP), Spanish Society of Rheumatology (SER), and Spanish Academy of Dermatology and Venereology (AEDV), on the diagnosis, treatment and prevention of Lyme borreliosis. Enferm. Infecc. Microbiol. Clin., 2023; 41: 40–45.
15. National Chamber of Laboratory Diagnosticians. Joint position of the Medical Parasitology Commission and the Medical Microbiology Team of the KIDL VI Term on testing ticks for the presence of pathogens of transmissible diseases in medical diagnostic laboratories.
16. Stupica D., Collinet-Adler S., Blagus R. and others: Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial. Lancet Infect. Dis., 2023; 23: 371–379.
17. Mahajan, Vikram K.. Lyme Disease: An Overview. Indian Dermatology Online Journal 14(5):p 594-604, Sep–Oct 2023. | DOI: 10.4103/idoj.idoj_418_22.
18. Lenormand C., Jaulhac B., Debarbieux S. and others.: Expanding the clinicopathological spectrum of late cutaneous Lyme borreliosis (acrodermatitis chronica atrophicans [ACA]): a prospective study of 20 culture- and/or polymerase chain reaction (PCR)-documented cases. J. Am. Acad. Dermatol., 2016; 74: 685–92.
19. Hansen K., Lebech A.M.: The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain, 1992; 115: 399–423.
20. Baldwin K.D., Brusalis C.M., Nduaguba A.M., Sankar W.N.: Predictive factors for differentiating between septic arthritis and Lyme disease of the knee in children. J. Bone Joint Surg. Am., 2016; 98: 721–728.
21. Forrester J.D., Meiman J., Mullins J. and others.: Centers for Disease Control and Prevention (CDC). Notes from the field: update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death – United States. MMWR Morb. Mortal Wkly. Rep., 2014; 63: 982–983.
22. N’Guyen Y., Lesaffre F., Metz D., de Martino S., Jaulhac B., Andréoletti L.: No serological evidence for Borrelia burgdorferi sensu lato infection in patients with dilated cardiomyopathy in Northern France. Infect. Dis. (Lond), 2016; 48: 763–764.
23. Lipowsky C., Altwegg M., Michel B.A., Brühlmann P.: Detection of Borrelia burgdorferi by species-specific and broad-range PCR of synovial fluid and synovial tissue of Lyme arthritis patients before and after antibiotic treatment. Clin. Exp. Rheumatol. 2003; 21: 271–272.
24. Leite L.M., Carvalho A.G., Ferreira P.L. and others.: Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. Inflammopharmacology, 2011; 19: 99–110.
25. Dehnert M. and others.: Seropositivity of Lyme borreliosis and associated risk factors: a population-based study in Children and Adolescents in Germany. PLoS One, 2012; 7: e41 321.
26. Feder H.M. Jr, Johnson B.J., O’Connell S. and others.: A critical appraisal of “chronic Lyme disease”. N. Engl. J. Med., 2007; 357: 1422–1430.
27. Klempner M.S., Hu L.T., Evans J. and others.: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med., 2001; 345: 85–92.
28. Smit P.W., Kurkela S., Kuusi M., Vapalahti O.: Evaluation of two commercially available rapid diagnostic tests for Lyme borreliosis. Eur. J. Clin. Microbiol. Infect. Dis., 2015; 34: 109–113.
29. Bockenstedt L.K., Radolf J.D.: Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it? Clin. Infect. Dis., 2014; 58: 946–948.
30. Liu S., Cruz I.D., Ramos C.C. and others.: Pilot Study of Immunoblots with Recombinant Borrelia burgdorferi Antigens for Laboratory Diagnosis of Lyme Disease. Healthcare (Basel), 2018; 14: 99.
31. Kwit N.A., Nelson C.A., Max R., Mead P.S.: Risk factors for clinician-diagnosed Lyme arthritis, facial palsy, carditis, and meningitis in patients from high-incidence states. Open Forum Infect. Dis. 2018; 5: ofx254.
32. Goettner G., Schulte-Spechtel U., Hillermann R., Liegl G., Wilske B., Fingerle V.: Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. J. Clin. Microbiol., 2005 43: 3602–3609
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zuzanna Wyleciał, Julia Ząber, Wiktoria Zamachowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 27
Number of citations: 0
